GHRH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-23. Numbers and descriptions here follow the published literature rather than marketing material.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Realizing that he cannot win with brute force, Neo allows Smith to assimilate him, which enables the machines to eradicate the Smith virus directly through his body. Unfortunately, the process also kills Neo. Neo's body is taken away by the machines in the Machine City, while below in Zion, the machines stop their attack and depart in deference to the peace that Neo bartered. The Matrix is rebooted and a beautiful sunrise appears over the horizon, created by Sati in Neo's honor.
UPMC Bedford, located in Everett, Pennsylvania. UPMC Chautauqua, located in Jamestown, New York, is a 317-bed hospital that was originally charted in 1885. It is the only domestic hospital located outside of Pennsylvania to become part of the UPMC system. UPMC East, a $250 million full-service, 155-bed hospital that opened in Monroeville, Pennsylvania, in July 2012. UPMC Horizon, which consists of the Greenville and Shenango Valley campuses. UPMC Jameson, located in New Castle, Pennsylvania. UPMC McKeesport, located in McKeesport, Pennsylvania. UPMC Northwest, located in Seneca, Pennsylvania. UPMC St. Margaret, a 248-bed acute care and teaching hospital in the northeast corner of Pittsburgh, near Aspinwall, PA, serving the residents of northeastern Allegheny County and the Alle-Kiski Valley. UPMC Central Pa which comprises seven hospitals, including its tertiary flagship UPMC Harrisburg, serves South Central Pennsylvania, operates the following seven community hospitals: UPMC Carlisle located in Carlisle, Pennsylvania UPMC Hanover located in Hanover, Pennsylvania UPMC Lititz located in Lititz, Pennsylvania UPMC Memorial located in York, Pennsylvania has 104 beds, five stories, and opened in 2019.
Respiratory stimulants: carotid chemoreceptor agonists (e.g. doxapram), 5-HT4 agonists (e.g. BIMU8), δ-opioid agonists (e.g. BW373U86) and AMPAkines (e.g. CX717) can all reduce respiratory depression caused by opioids without affecting analgesia, but most of these drugs are only moderately effective or have side effects which preclude use in humans. 5-HT1A agonists such as 8-OH-DPAT and repinotan also counteract opioid-induced respiratory depression, but at the same time reduce analgesia, which limits their usefulness for this application. Opioid antagonists (e.g. naloxone, nalmefene, diprenorphine) The initial 24 hours after opioid administration appear to be the most critical with regard to life-threatening OIRD, but may be preventable with a more cautious approach to opioid use. Patients with cardiac, respiratory disease and/or obstructive sleep apnoea are at increased risk for OIRD.
This is by inhibiting the norepinephrine transporter (NET) and preventing entry of tyramine into presynaptic noradrenergic neurons where tyramine induces the release of norepinephrine. As a result, NRIs may reduce the risk of tyramine-related hypertensive crisis in people taking MAOIs. Norepinephrine–dopamine reuptake inhibitors (NDRIs), like methylphenidate and bupropion, are also considered to be safe in combination with MAOIs. However, initiation at low doses and slow upward dose titration is advisable in the case of both NRIs and NDRIs due to possible potentiation of their effects and side effects by MAOIs. Selegiline may potentiate the effects of serotonergic psychedelics that are MAO-B substrates, such as 2C drugs like 2C-B, 2C-I, and 2C-E.
Sources: en.wikipedia.org
=== Development === Insecticides with systemic activity against sucking pests, which are safe to pollinators, are sought after, particularly in view of the partial bans on neonicotinoids. Revised 2023 guidance by registration authorities describes the bee testing that is required for new insecticides to be approved for commercial use.
== Changes for 2020 exam == The Central Board of Secondary Education (CBSE) has been conducting two separate Mathematics examinations in the class 10 board examination, starting from the 2020 session. Mathematics exam till 2019 was Mathematics (Standard), and an easier version, Mathematics (Basic), has been introduced. The option to choose mathematics is available on the registration form for the Class 10 CBSE board examination. Candidates are required to select their test choice while filling out the registration form for the CBSE Class 10 board examination 2020. Minister of Education, MoE (previously Minister of Human Resource Department, HRD), amid the coronavirus outbreak had ordered rescheduling of pending examinations. The exams rescheduled were to be conducted between 1 and 15 July. On 26 June, CBSE released as circular which cancelled the remaining exams and give scores based on the scores of the exams already taken by students. Some students of Delhi who were able to provide three or fewer exams were scored as per their performance in internal exams. This decision came after a judicial ruling.
=== D-ribose L-cysteine === D-ribose-L-cysteine (riboceine) is a chemical compound developed as a cysteine prodrug intended to increase endogenous production of glutathione, a naturally occurring intracellular antioxidant. Structurally, it consists of D-ribose, a pentose sugar involved in cellular energy metabolism, chemically bound to L-cysteine, an amino acid required for glutathione biosynthesis.
The Royal Air Force (RAF) provided surveillance and reconnaissance support, with an RAF surveillance plane tracked over the area where a Russian-linked tanker, Bella 1, was seized by US forces in January 2026. The UK provided one of its largest naval supply ships, the RFA Tideforce to support the US seizure of Bella 1 (renamed Marinera) in the North Atlantic, and UK military bases in the Atlantic were used by US planes and military assets involved in the operation.
== External links == What's in an Oil Drop? An Introduction to Fourier Transform Ion Cyclotron Resonance (FT-ICR) for Non-scientists National High Magnetic Field Laboratory Scottish Instrumentation Resource Centre for Advanced Mass Spectrometry Fourier-transform Ion Cyclotron Resonance (FT-ICR) FT-ICR Introduction University of Bristol
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.